Responding to the Evolving Treatment Paradigm for Myelofibrosis: Narratives in Collaboration
This activity has expired. Credit is no longer available.
1.0 Credit
Release Date: 12/20/2019 | Expiration Date: 12/19/2020
Estimated time to complete activity: 1.0 hour
In this CE/CME-certified activity you'll find a full-length JADPRO article on the role of the advanced practitioner in treating patients with myelofibrosis (MF). You'll also note several short videos featuring the author, Karen Schiavo, ARNP, AOCNP®, of Seattle Cancer Care Alliance, speaking with Lynn P., one of her patients living with MF. Don't miss a bonus Q&A session between Ms. Schiavo and JADPRO's Editor-in Chief, an Appendix that highlights the numerous risk stratification tools currently in use, and links to valuable resources for both patients and advanced practitioners.
Faculty
Karen M. Schiavo ARNP, AOCNP®
Seattle Cancer Care Alliance
Guest
Lynn P.
Patient
Read the article
Tell us about your practice
Loading...
Q&A With the Editor-in-Chief of JADPRO
In a bonus interview, Pamela Hallquist Viale, Editor-in-Chief of JADPRO, talks with author Karen Schiavo about what APs can do to best support their patients with MF.
Resources
For Patients
MPN10 Know Your Score
An app that enables patients to keep track of their MF symptoms.
Voices of MPN
A website devoted to raising awareness of myelofibrosis and other myeloproliferative neoplasms.
MPN Research Foundation
A 501(c)3 non-profit organization dedicated to stimulating original research in pursuit of new treatments for MF, PV, and ET. Based in Chicago. Follow on Twitter @MPN-RF.
Josie - MPN Advocate
@MPNAdvocate
Twitter account of an Australian social worker who is also an MPN patient.
MPN Advocates Network
Website of an organization in Switzerland that aims to create a global network of MPN patient groups. New members welcome.
Patient Power: Myeloproliferative Neoplasms
Website dedicated to empowering patients with cancer. Offers a section on myeloproliferative neoplasms. The co-founder, Andrew Schorr, has myelofibrosis.
For Advanced Practitioners
Ruben A. Mesa MD
@mpdrc
Twitter feed of this prominent clinical research specialist at UT Health San Antonio, Texas.
Research Outputs
Recent publications by this prolific author of research-based journal articles on myelofibrosis.
Bart Scott, MD
Myeloproliferative Neoplasms
Portal page offering a variety of recorded video programs featuring the director of hematology and hematologic malignancies at the Seattle Cancer Care Alliance.
Srdan Verstovsek, MD, PhD
Selected Publications
Recent publications by another prolific author of research-based journal articles on myelofibrosis.
Additional Resources
Myelofibrosis Clinical Trials
An online listing of myelofibrosis research trials actively recruiting patient volunteers.
MPN Clinical Trials
An online listing of myelofibrosis clinical trials. Hosted by the MPN Research Foundation.
MPN Connect
Website offering expert consultation to US healthcare professionals.
NCCN Guidelines
Updated at least annually, these guidelines provide detailed clinical guidance for members of the primary oncology care team, including an entire page of supportive care recommendations.
This activity, certified for CME/CE/CPE credit, is jointly provided by:
This activity is supported by an unrestricted educational grant from Incyte Corporation.
This activity has expired. Credit is no longer available.
1.0 Credit
Release Date: 12/20/2019 | Expiration Date: 12/19/2020
Estimated time to complete activity: 1.0 hour
In this CE/CME-certified activity you'll find a full-length JADPRO article on the role of the advanced practitioner in treating patients with myelofibrosis (MF). You'll also note several short videos featuring the author, Karen Schiavo, ARNP, AOCNP®, of Seattle Cancer Care Alliance, speaking with Lynn P., one of her patients living with MF. Don't miss a bonus Q&A session between Ms. Schiavo and JADPRO's Editor-in Chief, an Appendix that highlights the numerous risk stratification tools currently in use, and links to valuable resources for both patients and advanced practitioners.
Faculty
Seattle Cancer Care Alliance
Guest
Patient
Tell us about your practice
Loading...Q&A With the Editor-in-Chief of JADPRO
Resources
For Patients
MPN10 Know Your Score
An app that enables patients to keep track of their MF symptoms.
Voices of MPN
A website devoted to raising awareness of myelofibrosis and other myeloproliferative neoplasms.
MPN Research Foundation
A 501(c)3 non-profit organization dedicated to stimulating original research in pursuit of new treatments for MF, PV, and ET. Based in Chicago. Follow on Twitter @MPN-RF.
Josie - MPN Advocate
@MPNAdvocate
Twitter account of an Australian social worker who is also an MPN patient.
MPN Advocates Network
Website of an organization in Switzerland that aims to create a global network of MPN patient groups. New members welcome.
Patient Power: Myeloproliferative Neoplasms
Website dedicated to empowering patients with cancer. Offers a section on myeloproliferative neoplasms. The co-founder, Andrew Schorr, has myelofibrosis.
For Advanced Practitioners
Ruben A. Mesa MD
@mpdrc
Twitter feed of this prominent clinical research specialist at UT Health San Antonio, Texas.
Research Outputs
Recent publications by this prolific author of research-based journal articles on myelofibrosis.
Bart Scott, MD
Myeloproliferative Neoplasms
Portal page offering a variety of recorded video programs featuring the director of hematology and hematologic malignancies at the Seattle Cancer Care Alliance.
Srdan Verstovsek, MD, PhD
Selected Publications
Recent publications by another prolific author of research-based journal articles on myelofibrosis.
Additional Resources
Myelofibrosis Clinical Trials
An online listing of myelofibrosis research trials actively recruiting patient volunteers.
MPN Clinical Trials
An online listing of myelofibrosis clinical trials. Hosted by the MPN Research Foundation.
MPN Connect
Website offering expert consultation to US healthcare professionals.
NCCN Guidelines
Updated at least annually, these guidelines provide detailed clinical guidance for members of the primary oncology care team, including an entire page of supportive care recommendations.
Responding to the Evolving Treatment Paradigm for Myelofibrosis: Narratives on Collaboration
A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
Jointly provided by
|
Release date: December 20, 2019 |
Estimated time to complete activity: 1.0 hour |
|
Expiration date: December 19, 2020 |
|
|
Certified for CE by: |
|
|
Annenberg Center for Health Sciences at Eisenhower |
Journal of the Advanced Practitioner |
This activity is supported by an unrestricted educational grant from Incyte Corporation.
Faculty
Karen Schiavo, ARNP, Seattle Cancer Care Alliance, Seattle, Washington
Intended Audience
The activity’s target audience will consist of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
Learning Objectives
After completing this educational activity, participants should be able to:
- Evaluate clinical manifestations associated with myelofibrosis (MF) that have been most significantly linked to diminished quality of life
- Interpret the clinical significance of data from clinical trials evaluating current and novel agents for MF
- Develop plans for managing adverse events associated with agents used to treat MF
- Devise risk-stratified treatment plans in accordance with current guidelines and emerging evidence
Continuing Education
Statement of Credit
Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.
Accreditation and Designation Statements
Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.0 contact hour may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider No. 13664, for 1.0 contact hour.
Pharmacists.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-19-142-H01-P. This program is designated for up to 1.0 contact hour (0.10 CEU) of continuing pharmacy education credit. This is a knowledge-based activity.
Disclosures
Relationships of Faculty and Planners
All individuals in a position to control the content of this activity (eg, planners, faculty, reviewers) must disclose all financial relationships with commercial interests that may have a bearing on its subject matter. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with its policies and procedures. Participants should assess the impact (if any) of the disclosed information on the educational value of the activity.
Faculty
Karen Schiavo, ARNP, has nothing to disclose.
Planners
Charles Willis, Director of Continuing Education, consults for Pfizer, Inc. All other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose. Harborside and Harborside Medical Education staff have no potential conflicts of interest to disclose.
Dorothy Caputo, MA, BSN, RN, EduPro Resources, LLC, has nothing to disclose.
Reviewers
Justin Speyer, ARNP, is a shareholder of AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer, and Procter & Gamble.
Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.
Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food & Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
Disclaimer
The opinions expressed in this activity are those of the faculty and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any therapeutic agent or approach to diagnosis or patient management.